Cardiff OncologyCRDF -7.58%48 ROC (Joel Greenblatt) % is -4,687.64% as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.42 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,319 Biotechnology companies, Cardiff Oncology ranks worse than 80.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cardiff Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4,687.64%.
The historical rank and industry rank for Cardiff Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:
CRDF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3338.12 Med: -1291.87 Max: -763.57
Current: -3338.12
During the past 13 years, Cardiff Oncology's highest ROC (Joel Greenblatt) % was -763.57%. The lowest was -3338.12%. And the median was -1291.87%.
CRDF's ROC (Joel Greenblatt) % is ranked worse than 80.59% of 1319
companies
in the Biotechnology industry
Industry Median: -291.86
vs CRDF: -3338.12
Cardiff Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.90% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Cardiff Oncology ROC (Joel Greenblatt) % Related Terms
Cardiff Oncology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRDF vs MAIA, TELO, OSTX: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Cardiff Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -4,687.64% mean?
Cardiff Oncology (CRDF) has a ROC (Joel Greenblatt) % of -4,687.64% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #1063 out of 1319 companies in the Biotechnology industry, placing it in the top 80.6%.
Is Cardiff Oncology's ROC (Joel Greenblatt) % too high?
Cardiff Oncology's current ROC (Joel Greenblatt) % is -4,687.64%. Based on the distribution chart, Cardiff Oncology ranks #1063 out of 1319 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's ROC (Joel Greenblatt) % compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #1063 out of 1319 companies for ROC (Joel Greenblatt) %. This places Cardiff Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current ROC (Joel Greenblatt) % is -4,687.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.42, compared to a current price of $1.27 — trading 10.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is -4,687.64%. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current ROC (Joel Greenblatt) % is -4,687.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.27 is trading 10.9% below its estimated GF Value™ of $1.42.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
ROC (Joel Greenblatt) %: -4,687.64%
GF Value™: $1.42 vs. price of $1.27 (10.9% below fair value)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score
Get the complete analysis for CRDF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
